[{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"TB Alliance","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Pretomanid","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ TB Alliance","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ TB Alliance"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma ","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma "},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Jacobson Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma Group"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Sinopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Shanghai Fosun Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ Shanghai Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Raziel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RZL 012","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Fosun Pharmaceutical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fosun Pharmaceutical","amount2":0.44,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Fosun Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ BioNTech"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ BioNTech"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Kintor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Helsinn","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Helsinn"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Neovii","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Rabbit Anti-human T-lymphocyte Globulin","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Omicron BA.4\/BA.5-adapted Bivalent Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Shanghai Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharma"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Artemisinin-based Antimalarial Drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Ardelyx","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Palatin Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Artemether","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ GHIT Fund"}]

Find Clinical Drug Pipeline Developments & Deals by Fosun Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : Artemether,Lumefantrine,Amodiaquine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : GHIT Fund

                          Deal Size : $3.3 million

                          Deal Type : Financing

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 08, 2023

                          Lead Product(s) : Bremelanotide Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Recipient : Palatin Technologies

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The agreement provides Fosun Pharma the rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome with constipation and for the treatment of hyperphosphatemia related to ch...

                          Brand Name : Xphozah

                          Molecule Type : Small molecule

                          Upfront Cash : $12.0 million

                          July 13, 2023

                          Lead Product(s) : Tenapanor

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Recipient : Ardelyx

                          Deal Size : $125.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Artesun (artesunate) is rapidly metabolized into an active metabolite DHA which contains an endoperoxide bridge that is activated by heme iron leading to oxidative stress, inhibition of protein and nucleic acid synthesis, which decreases parasite growth ...

                          Brand Name : Artesun

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 26, 2023

                          Lead Product(s) : Artemisinin-based Antimalarial Drug

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Hansizhuang (serplulimab), a recombinant humanised anti-PD-1 monoclonal antibody injection, is the first innovative monoclonal antibody developed by Henlius for the treatment of MSI-H solid tumours and squamous non-small cell lung cancer (sqNSCLC).

                          Brand Name : Hansizhuang

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 07, 2023

                          Lead Product(s) : Serplulimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Shanghai Henlius Biotech

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : HANSIZHUANG (serplulimab), a recombinant humanised anti-PD-1 monoclonal antibody injection, is the first innovative monoclonal antibody developed by Henlius for the first-line treatment of SCLC.

                          Brand Name : Hansizhuang

                          Molecule Type : Large molecule

                          Upfront Cash : $143.6 million

                          December 27, 2022

                          Lead Product(s) : Serplulimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Shanghai Henlius Biotech

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The results suggest that a booster dose of the Omicron BA.4/BA.5-adapted bivalent vaccine Comirnaty (tozinameran) may induce a higher level of protection against the Omicron BA.4 and BA.5 sublineages than the companies’ monovalent COVID-19 vaccine.

                          Brand Name : Comirnaty

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          December 23, 2022

                          Lead Product(s) : Tozinameran

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Recipient : BioNTech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Pre-clinical data showed a booster dose of Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 11, 2022

                          Lead Product(s) : Omicron BA.4/BA.5-adapted Bivalent Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Recipient : BioNTech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon® (Rabbit Anti-human T-lymphocyte Globulin) to Fosun Pharma Industry.

                          Brand Name : Grafalon

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 07, 2022

                          Lead Product(s) : Rabbit Anti-human T-lymphocyte Globulin

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Recipient : Neovii

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Helsinn will grant Fosun an exclusive license to distribute, promote and sell the following products in the aforesaid territory: Aloxi (Palonosetron hydrochloride), Akynzeo (Netupitant and Palonosetron hydrochloride) and NEPA (Fosnetupitant and Palonoset...

                          Brand Name : Aloxi

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 12, 2021

                          Lead Product(s) : Palonosetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Helsinn Advanced Synthesis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank